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Abstract. Antisense oligonucleotides (oligos) have been employed against in vivo and in vitro prostate cancer models. While most
oligos target growth factors or their receptors, others are directed against inhibitors of apoptosis or mediators of androgen activity.
In previous experiments, mono- and bispeciﬁc oligos directed against bcl-2 suppressed both the targeted bcl-2 protein (an inhibitor
of apoptosis) and non-targeted caspase-3 (a promoter of apoptosis), potentially negating the eﬀect of therapeutic bcl-2 inhibition.
Subsequently we reported that AR and p300 expression were signiﬁcantly enhanced by these oligos. In a continuation of this
study, we now report that the expression of another androgen receptor co-stimulatory protein, CREB binding protein (CREBBP),
is not similarly increased. These data suggest that oligo treatment directed against bcl-2 can be evaded through compensatory
increases in AR and p300 expression. Increased AR and p300 expression may transition the tumor to a more dediﬀerentiated
and aggressive phenotype. However, not all co-stimulating proteins (CREBBP) are involved, and this may be important when
controlling unanticipated (compensatory) eﬀects of gene therapy.
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1. Introduction
Eﬀective therapeutics directs their activity towards unique
characteristics of etiologic agents (like bacterial cell walls,
ribosomes or viral encoded enzymes). However, even dedif-
ferentiated cancer cells are not substantially diﬀerent from
non-cancerous (diﬀerentiated cells). They use the same
biochemical pathways and, unless virally induced, most are
(evenantigenically)similartonormalcells.Theeﬀectiveness
of chemotherapy capitalizes on the fact that within a tumor a
greater proportion of cells are in the process of replicating.
Therefore, some aspect of DNA synthesis or repair is
usuallytargeted.In prostateand breastcancers, growth factor
(hormonal or protein) deprivation provides another type
of therapy where orchiectomy or biochemical analogs or
agonists block/interfere with steroid production or activity.
Another approach could target transcriptional activity ini-
tiated by the DNA hormone response elements recognized2 The Open Access Journal of Science and Technology
by the hormonal binding receptors (androgen receptor [AR],
or estrogen receptor [ER]) or their co-activators (p300 and
cAMP response element binding [CREB] binding protein
[CREBBP]) which are more prevalent in advanced, hormone
insensitive, disease [1]. However, for most chemotherapy
tumor cell speciﬁcity is relative, often lacking, and most
agents have signiﬁcant toxicity towards other replicating
cells, producing side eﬀects in tissues or organs (gut or bone
marrow) with rapid cell replenishment.
Gene therapy is based on a similar premise and while
eﬀective protocols require either translational suppression
(antisenseoligonucleotides[oligos])orreplacement(ofinac-
tivated,mutatedordeletedsuppressorgeneslikephosphatase
and tensin homolog (PTEN) technology [2] both tumor and
normal cells still express mostly the same genes. Targets
for gene therapy are found in many pathways and it is
likely that hundreds (or thousands) of genes are involved
in malignant transformation. Although tumors can express
an overall altered pattern of gene expression, the levels
of many growth regulatory genes are similar to normal
cells. Resistance develops because the biochemical pathways
involved are complex and highly regulated by stimulatory
and inhibitory factors, many altered by therapy. In addition,
we report that tumors can alter their dependence upon single
geneinﬂuencesbyrelyinguponothersthroughcompensation
[3].
Tumors are essentially heterogeneous masses of rapidly
growing and selectively adapted cells whose sole purpose
is to survive and replicate. While doing so, those bear-
ing mutations able to evade therapeutic interventions are
clonally selected. The best example is the emergence of
hormoneinsensitiveprostatecancercellsfollowingandrogen
deprivation therapy, resulting in the increased expression
of the autocrine loop consisting of transforming growth
factor-alpha (TGF-𝗼) and its binding site the epidermal
growth factor receptor (EGFR). In 1994, these were the ﬁrst
targets suggested applicable for treatment of prostate cancer
employing antisense oligos [4].
As bacteria and viruses mutate to evade antibiotic and
antiviral agents, tumor cells are under similar selective
pressure to evade therapy. Although newly developed forms
of gene therapy provide speciﬁc ways to inhibit uncontrolled
growth or promote (re-establish) apoptosis, the unintended
consequences of intervention are poorly understood, and
some may compensate for the intended eﬀect.
Gene therapy is already being clinically applied for the
treatment of human tumors including those of the prostate,
and antisense oligos have been administered targeting the
inhibitors bcl-2 and clusterin in eﬀorts to restore apoptosis
following radio- [5, 6] or chemotherapy [7]. If such therapy
is to be successful, it is important to examine mechanisms by
which tumors can evade this therapy through compensation.
We recently reported [3] that, in the LNCaP tumor model,
inhibition of bcl-2 with antisense oligos suppressed the
expression of the apoptotic promoter caspase-3. In another
form of compensation, we also found that expression of
the AR was increased [8] as was the transcriptional co-
activator p300 [9], which is usually associated with and
more highly expressed in advanced prostate tumors [1]. Our
earlier studies [8, 9] evaluated expression of several co-
activators of the AR, the cytokines IL-4 and IL-6. The results
identiﬁed an increased IL-6 expression but no similar eﬀect
in the IL-4 co-activator [9]. In this study we evaluate another
co-activator of the AR, CREBBP. CREBBP is universally
expressed and acts in association with many transcriptional
factors including the AR. Functionally, the protein has
histone acetyltransferase activity and provides a scaﬀold
to the transcriptional complex and shares some sequence
homology with p300 [10]. Enhanced AR activity could not
only select cells which again evade apoptosis and enhance
tumor progression (even with bcl-2 suppression), but could
also indicate the emergence of a more aggressive (hormone
insensitive) phenotype. For gene therapy to ultimately be
successful it must be made more speciﬁc or mechanisms of
compensation identiﬁed and suppressed.
2. Materials and Methods
2.1. Oligonucleotides. Oligos (mono- or bispeciﬁc) were
purchased from Euroﬁns MWG Operon (Huntsville, AL).
Each was phosphorothioated on three terminal bases at 5’
and 3’ positions. Stock solutions were made to a ﬁnal
concentration of 625𝜇M in sterile Dulbecco PBS.
Base Sequences
Each oligo contained at least one CAT sequence and
targetedtheareaadjacenttothemRNAAUGinitiationcodon
for the respective targeted protein (EGFR or bcl-2).
MR4 (monospeciﬁc targeting bcl-2) T-C-T-C-C-C-A-G-
C-G-T-G-C-G-C-C-A-T
MR24 (bispeciﬁc targeting EGFR/bcl-2) G-A-G-G-G-T-
C-G-C-A-T-C-G-C-T-G-C-T-C- T-C-T-C-C-C-A-G-C-G-
T-G-C-G-C-C-A-T
MR42 (bispeciﬁc targeting bcl-2/EGFR) T-C-T-C-C-C-
A-G-C-G-T-G-C-G-C-C-A-T-G-A-G-G-G-T-C-G-C-A-T-
C-G-C-T-G-C-T-C
Cell Culture
LNCaP cells were grown in RPMI 1640 supplemented
with 10% bovine serum, 1% L-glutamine and 1% peni-
cillin/streptomycin in a 5% CO2 incubator. Log phase cells
were harvested using EDTA/trypsin and equally distributed
into 75 cm2 ﬂasks (Corning, NY). At intervals media were
either supplemented or replaced with fresh.
Oligo Treatment Prior to RT-PCR
Fours days prior to oligo addition, when cell density
approached75%conﬂuence,10mloffreshmediawasadded.
Cells were incubated for an additional 3 days before 5 ml
of media was replaced with fresh the day before oligos
were added. 100𝜇l of stock oligos were added to bring
the ﬁnal concentration to 6.25𝜇M. Incubation proceeded
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for an additional 24 hours in the presence or absence of
monospeciﬁc MR4, or the MR24 and MR42 bispeciﬁcs.
RNA Extraction
Following treatment, media was removed, a single ml of
cold (4∘C) RNAzol B was added to each 75 cm2 culture
ﬂask and the monolayer lysed by repeated passage through
a pipette. All procedures were performed at 4∘C. The lysate
was removed, placed in a centrifuge tube to which 0.2 ml
of chloroform was added, and shaken. The mixture stayed
on ice for 5min, was spun at 12,000g for 15min, and the
upperaqueousvolumeremovedandplacedinafreshtube.An
equal volume of isopropanol was added, the tube shaken, and
allowedtostayat4∘Cfor15minbeforesimilarcentrifugation
to pellet the RNA. The supernatant was removed, the pellet
washed in a single ml of 75% ethanol, then spun for 8min at
7500g. The ethanol was pipetted oﬀ and the formed pellet air
dried at −20∘C.
RNA Quantitation
RNA was resuspended in 250𝜇l of diethypyrocarbonate
(DEPC) treated H2O, and quantitated using a Qubit ﬂorom-
eter and Quant-iT RNA assay kit (Invitrogen: Grand Island,
NY). DEPC is an inhibitor of RNase activity.
Reverse Transcriptase-PCR
Extracted RNA was diluted in DEPC treated water to
40𝜇g/𝜇l. 1–4𝜇l of this RNA was added to1𝜇l of both sense
and antisense primers (forward and reverse sequences from
RealTimePrimers: Elkins Park, PA) for bcl-2, AR, p300 and
CREBBP. From a kit purchased from Invitrogen the fol-
lowing reactants were added for Reverse Transcriptase-PCR
(RT-PCR): 25𝜇l of 2X reaction mixture, 2𝜇l SuperScript III
RT / platinum Taq mix, tracking dye, and 3𝜇l MgSO4 (of a
5mM stock concentration). DEPC treated water was added
to yield a ﬁnal volume of 50𝜇l. RT-PCR was performed
for 2 X 25 cycles using the F54 program in a Sprint PCR
Thermocycler. As a control for RT-PCR product production,
human actin expression was tested in RNA extracted from
HeLa cells which was provided in a kit purchased from
Invitrogen (in the reaction mixture, no MgSO4 was included,
the diﬀerence compensated for by 3𝜇l of DEPC treated
water).
Primers
Actin
Forward primer sequence: 5’ CAA ACA TGA TCT GGG
TCA TCT TCT C 3’
Reverse primer sequence: 5’ GCT CGT CGT CGA CAA
CGG CTC
PCR product produced was 353 base pairs in length
Bcl-2
Forwardprimersequence:5’GAGACAGCCAGGAGA
AAT CA 3’
Reverse primer sequence: 5’ CCT GTG GAT GAC TGA
GTA CC 3’
PCR product produced was 127 base pairs in length.
Androgen Receptor
Forwardprimersequence:5’CGGAAGCTGAAGAAA
CTT GG 3’
Reverse primer sequence: 5’ ATG GCT TCC AGG ACA
TTC AG 3’
PCR product produced was 155 base pairs in length.
p300
Forward primer sequence: 5’ CGC TTT GTC TAC ACC
TGC AA 3’
Reverse primer sequence: 5’ TGC TGG TTG TTG CTC
TCA TC 3’
PCR product produced was 167 base pairs in length.
CREBBP
Forward primer sequence: 5’ CAC CAG CAG ATG AGG
ACT CT 3’
Reverse primer sequence: 5’ TAC ACC GGT GCT AGG
AGG AG 3’
PCR product produced was 222 base pairs in length
Detection and Quantitation of Product
Agarose Gel Electrophoresis
1.5% agarose gels were prepared in a 50 ml volume of
TBE buﬀer (1X solution: 0.089 M Tris borate and 0.002M
EDTA, pH 8.3), containing 3𝜇l of ethidium bromide in a
Fisher Biotest electrophoresis system. Samples were run for
2 hours at a constant voltage of 70 using a BioRad 1000/500
power supply source. To locate the ampliﬁed PCR product,
3𝜇l of a molecular marker (Invitrogen) which contained a
sequence of bases in 100 base pair increments (Invitrogen)
as well as 2𝜇l of a sucrose based bromphenol blue tracking
dye were run in each gel.
Quantitation
Gels were visualized under UV light and photographed
using a Canon 800 digital camera. Photos were converted to
black and white format and bands quantitated using Mipav
software provided by the National Institute of Health. Means
and standard deviations were compared using Student t-tests
to determine signiﬁcance.
3. Results and Discussion
3.1. Bcl-2 Expression. As a control (data not shown) for RT-
PCR sequence replication human actin expression was tested
in RNA extracted from HeLa cells Figure 1.
LNCaP cells incubated for 24 hours in the presence
of 6.25𝜇M of oligos suppressed Bcl-2 expression, and
support the ﬁnding of comparable biologic activity in both
mono- and bispeciﬁc oligos measured in the in vitro cell
growth inhibition experiments [11]. When photographs of
the identiﬁed product bands were scanned on agarose gels
and quantitated using Mipav software, in a series of runs, the
greatest expression of bcl-2 was always found in untreated
LNCaP cells. Those treated with oligos, whether mono-
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Figure 1: Human Actin Control in an Agarose Gel.
or bispeciﬁc, produced bands which indicated obvious (to
the naked eye) suppression. For each oligo evaluated, the
greatest amount of suppression measured approached 100%
for the mono-speciﬁc MR4; and for the bispeciﬁcs MR24 and
MR42, 86% and 100%, respectively. Suppression was found
in both repeat RT-PCR runs with bcl-2 primers, as well as in
repetitive agarose gel quantiﬁcations. Representative bands
are presented Figure 2.
3.2. AR Expression. Comparable amounts of extracted RNA
from LNCaP cells treated with either mono- or bispeciﬁc oli-
gos directedagainstbcl-2 (and EGFR in the bispeciﬁcs) were
then evaluated by RT-PCR using primers directed against
AR. When background intensity was subtracted, the relative
intensity of all bands corresponding to AR representing cells
treated with MR4, MR24 and MR42 compared to controls
were enhanced 31.2% ± 26.0 (P = 0.015), 58.5% ± 51.4
(P = 0.019) and 53.1% ± 45.9 (P = 0.019). These results
(N = 6) were pooled from both duplicate RT-PCR runs and
gels, and indicate similar (signiﬁcant) enhancement of AR
activity is produced by each oligo type. Representative bands
are presented Figure 3.
3.3. p300 Expression. Comparable amounts of extracted
RNA from LNCaP cells treated with either mono- or
bispeciﬁc oligos directed against bcl-2 (and EGFR in the
bispeciﬁcs) were then evaluated by RT-PCR using primers
directed against p300. When background intensity was
subtracted, the relative intensity of all bands corresponding
to p300 representing cells treated with MR4, MR24 and
MR42 compared to controls were increased 82.9% ± 51.9
(P = 0.006), 93.0% ± 87.3 (P = 0.044) and 105.4% ±
65.9 (P = 0.007). These results (N = 6) were pooled from
both duplicate RT-PCR runs and gels, and indicate similar
(signiﬁcant) enhancement of p300 activity is produced
by each oligo type. Representative bands are presented in
Figure 4.
CREBBP Expression
ComparableamountsofextractedRNAfromLNCaPcells
treatedwitheithermono-orbispeciﬁcoligosdirectedagainst
bcl-2 (and EGFR in the bispeciﬁcs) were then evaluated
by RT-PCR using primers directed against CREBBP. When
background intensity was subtracted, the relative intensity
of all bands corresponding to CREBBP representing cells
treated with MR4, MR24 and MR42 compared to controls
were varied. Although signiﬁcant decreases were found in
both the monospeciﬁc MR4 (−32.1% ± 5.7; P < 0.05) and
bispeciﬁc MR42 (−26.8% ± 32.3; P < 0.05) there was no
signiﬁcant change in MR24. This pattern (where similar
changes are not seen in both bispeciﬁcs) is unique in the
many proteins we have examined, and we conclude that
unlike the increased expression of AR and p300, there is no
enhancement of this transcription co-activator. These results
(N = 6) were pooled from both duplicate PCR runs and gels.
Representative bands are presented in Figure 5.
The androgen receptor (AR) (also known as NR3C4;
nuclear receptor subfamily 3, member 4) plays a principle
role in male sexual development, prostate function, cancer
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Figure 2: Bcl-2 Expression is Suppressed by Oligos as Indicated in a Representative Agarose Gel.
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Figure 3: Androgen Receptor Expression is Enhanced by Oligos as Indicated in a Representative Agarose Gel.
progression and target for treatment strategies. Following
cytoplasmic binding of the AR to testosterone or its dihy-
drotestosterone metabolite, it undergoes a conformational
change accompanied by dissociation of heat shock proteins
with translocation into the cell nucleus. AR dimerizes, binds
to hormone response elements of the DNA, and acts as a
transcription factor enhancing synthesis of growth stimulat-
ing proteins, including insulin-like growth factor (IGF) [12].
In addition to IGF, other growth factors like transforming
growth factor-alpha (TGF-𝗼) acting through their respective
receptors (like the epidermal growth factor receptor [EGFR]
which binds TGF-𝗼) contribute to unregulated prostate
cancer growth. These protein factors and their receptors
are targets for oligo mediated suppressive therapy [4].
Although disruption of this process by androgen deprivation
provides the rationale for most types of prostate cancer
treatment, most tumors recur in an androgen insensitive
form within a few years. At this stage, genes are driven
towardstranscriptionbyAR,coactivatingtranscriptionfactor
p300 and its homolog, CREBBP. p300 is essential for cell
growth and governs the expression of cyclins regulating the
transition between G1, S, G2 and M phases of mitosis [13].
ActingwithIL-6,p300/CREBBPplaysaroleintheandrogen
independent expression of prostate speciﬁc antigen (PSA)
[14]. In the LNCaP model, administration of R1881 reduces
bothCREBBPmRNAandtheencodedCREBBPproteinand
suggests, that following androgen ablation, the expression of
some coactivators increase and contribute to a state of AR
hypersensitivity [15]. Treatment of prostate cancer cells with
siRNAdirectedagainstp300reducescancercellgrowth[15],
and eliminates the ability of IL-6 to induce PSA [15]. Since
both transcriptional coactivator proteins p300 and CREBBP
are expressed to a greater extent in advanced prostate cancer
[13], well diﬀerentiated, androgen sensitive, LNCaP cells
would be expected to have relatively low expression of p300,
and this has been demonstrated[9]. The enhanced expression
seenfollowingoligotreatment[9]makesitsinductionappear
more impressive, and implies transition to a gene expression
pattern associated with later stage (androgen insensitive)
disease. This suggests that oligo treatment directed against
bcl-2, not only can be evaded through compensatory changes
in expression which encourage tumor growth, but may
also contribute to further dediﬀerentiation and hormone
insensitivity.
Innovative protocols to disrupt androgen driven tumor
progression have employed antisense oligos directed against
the enzyme for conversion of testosterone to dihydrotestos-
terone (5-alpha reductase), heat shock proteins, p300 and the
AR itself. LNCaP cells express an AR which is mutated in
the binding domain however the Eder [16] and Rubenstein
groups [17] have separately demonstrated growth inhibition
in this in vitro model employing oligos.
Gene therapy is a complex process requiring multiple
pathways (and the regulatory proteins) to be simultaneously
regulated. In addition, the “driver genes” (usually kinases)
which greatly inﬂuence tumor growth must be distinguished
| http://www.agialpress.com/6 The Open Access Journal of Science and Technology
 
   
                               Untreated    Treated           Treated       Treated    
MR4                MR24          MR42 
       
82.9±5.9       93.0±87.3    105.4±65.9 
  P = 0.006           0.044            0.007  
p300 is a 167 base pair product
 
Percent_Enhancement  
Figure 4: p300 Expression is Enhanced by Oligos as Indicated in a Representative Agarose Gel.
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Figure 5: CREBBP Expression is Not Enhanced by Oligos as Indicated in a Representative Agarose Gel.
andtargetedratherthansimilarlymutated“passengergenes.”
Tofurthercomplicateantisensemediatedgenetherapy,some
oligos are able to bind to either targeted or non-targeted
proteins as aptamers, although in these studies, no such
selection or capacity was evaluated. Lastly, in addition to the
eﬀects upon non-targeted proteins, no studies have yet been
directed to evaluate additional regulation of protein activity
at the microRNA level.
Oligos (produced by Oncogenex Pharmaceuticals) have
reached clinical trials for the treatment of prostate cancer
(OGX-011), while others remain in preclinical development
(OGX-225). Often administered in combination with tra-
ditional chemotherapy, these oligos target bcl-2, clusterin
(OGX-011 in Phase II testing), heat shock protein 27 (OGX-
427) or insulin growth factor binding proteins (OGX-225)
(16). Many represent eﬀorts to restore tumor apoptosis by
eliminating apoptosis inhibitors bcl-2 [5–7], or clusterin
(OGX-11) associated with treatment resistance. For (tumor
suppressor) genes which are either diminished or lacking in
expression gene transfection has been attempted in prostate
cells which contain a mutated PTEN [2].
Although antisense oligos are speciﬁcally directed
through complementary base pairing to inhibit mRNA
translation of genes, there can be secondary or downstream
eﬀects on non-targeted genes following oligo mediated bcl-2
suppression [3, 8]. The eﬀectiveness of bcl-2 and overall
apoptosis activity is highly regulated and dependent upon
the expression of many stimulatory, inhibitory, stabilizing
factors, as well as the ratio between these proteins. As
demonstrated, the speciﬁc suppression of one apoptosis
inhibitory protein (bcl-2) is compensated by the suppression
of a non-targeted promoter, caspase-3 [3]. Clinically these
types of experiments are important because they suggest
that for oligo mediated bcl-2 suppression to be eﬀective
caspase-3 activity should be either maintained or enhanced
[3]. Other compensatory alterations are being evaluated,
and could involve the enhanced expression of non-targeted
apoptosis suppressors, producing a similar eﬀect (evasion
of re-established apoptosis following bcl-2 suppression).
GrowthstimulatoryproteinslikeTGF-𝗼,EGFRorIGFcould
also be enhanced. In these experiments bispeciﬁc oligos also
targeted EGFR. However, in previous experiments we found
that growth inhibition produced by monospeciﬁc oligos
directed against EGFR was not accompanied by decreased
mRNA expression [19]. Currently Genta is conducting a
phase 3 test using oligos (Genasense; oblimersen) directed
against bcl-2 for treating melanoma, chronic lymphocytic
| http://www.agialpress.com/The Open Access Journal of Science and Technology 7
leukemia and various solid tumors [20], but compensatory
eﬀects produced by this agent have not (yet) been reported.
Tumors are resilient in their eﬀorts to overcome (even
newly developed) therapeutics and become resistant. If
gene therapy is to be eﬀective, we must understand how
primary eﬀects evoke compensatory changes. It would also
be signiﬁcant to see whether these changes are replicated
in an in vivo model. If these lead to enhanced expression of
undesired proteins, the oligo approach can again be applied.
If antisense technology is to be fully exploited multivalent
forms (as proposed) can be developed to suppress multiple
proteins [21].
This year (2013) the American Cancer Society (ACS)
estimates that in spite of early detection, screening for
prostate speciﬁc antigen (PSA) and more eﬀective treatments
forlocalizeddisease,intheUnitedStatestherewillbe29,720
deaths from prostate cancer in addition to 238,590 newly
diagnosed cases [22]. New types of treatment, including
gene therapy and translational inhibition must be developed
and employed (probably in combination with traditional
androgen ablation).
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Dear Colleagues,
Although publications covering various aspects of nuclear receptors 
(NRs) appear every year in high impact journals, these publications are 
virtually buried among an overwhelming volume of articles that are only 
peripherally related to NRs. ￿   e latter fact prompted a group of promi-
nent scientists active in the ￿  eld of nuclear receptor research to conclude 
that gathering publications on this superfamily of receptors under one 
umbrella would provide an invaluable resource for a broad assemblage of 
scientists in the ￿  eld; thus the idea for a new journal, Nuclear Receptor 
Research, was born. 
I am pleased to share with you that Nuclear Receptor Research is now 
a reality as an open access peer-reviewed journal devoted to publishing 
high-quality, original research and review articles covering all aspects of 
basic and clinical investigations involving members of the nuclear recep-
tor superfamily. Nuclear Receptor Research has an editorial board com-
prised of a group of renowned scientists from around the world. Board 
members are committed to make Nuclear Receptor Research a vibrant 
forum showcasing global e￿  orts in this ever-expanding area of research. 
We believe that the impact and visibility of papers related to nuclear re-
ceptors will be signi￿  cantly enhanced by appearing in a journal devoted 
exclusively to nuclear receptors. In addition, it is hoped that Nuclear Re-
ceptor Research will serve as a catalyst to encourage collaborative stud-
ies as well as to foster interdisciplinary initiatives within this expansive 
and dynamic ￿  eld.  For these reasons, I invite you to consider Nuclear 
Receptor Research (http://www.agialpress.com/journals/nrr/) as a 
vehicle to share your novel research ￿  ndings as well as your vision for 
the future of nuclear receptor research with your colleagues around the 
world.
      Mostafa Badr
      Editor-in-Chief
      Nuclear Receptor Research